AU2023213905A1 - Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof - Google Patents

Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof Download PDF

Info

Publication number
AU2023213905A1
AU2023213905A1 AU2023213905A AU2023213905A AU2023213905A1 AU 2023213905 A1 AU2023213905 A1 AU 2023213905A1 AU 2023213905 A AU2023213905 A AU 2023213905A AU 2023213905 A AU2023213905 A AU 2023213905A AU 2023213905 A1 AU2023213905 A1 AU 2023213905A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023213905A
Other languages
English (en)
Inventor
Xin Cheng
Yingtao LIU
Luoheng QIN
Feng Ren
Huaxing YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InSilico Medicine IP Ltd
Original Assignee
InSilico Medicine IP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InSilico Medicine IP Ltd filed Critical InSilico Medicine IP Ltd
Publication of AU2023213905A1 publication Critical patent/AU2023213905A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023213905A 2022-01-28 2023-01-28 Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof Pending AU2023213905A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022074739 2022-01-28
CNPCT/CN2022/074739 2022-01-28
CN2022140318 2022-12-20
CNPCT/CN2022/140318 2022-12-20
PCT/CN2023/073579 WO2023143520A1 (en) 2022-01-28 2023-01-28 Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2023213905A1 true AU2023213905A1 (en) 2024-07-11

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023213905A Pending AU2023213905A1 (en) 2022-01-28 2023-01-28 Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Country Status (12)

Country Link
US (1) US20250101019A1 (https=)
EP (1) EP4469456A4 (https=)
JP (1) JP2025502943A (https=)
KR (1) KR20240142481A (https=)
CN (1) CN118871439A (https=)
AR (1) AR128383A1 (https=)
AU (1) AU2023213905A1 (https=)
CA (1) CA3247162A1 (https=)
IL (1) IL313821A (https=)
MX (1) MX2024009216A (https=)
TW (1) TW202340190A (https=)
WO (1) WO2023143520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CN121793967A (zh) * 2023-07-06 2026-04-03 英矽智能科技知识产权有限公司 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912874A1 (en) * 1990-08-15 1992-02-26 British Bio Technology Compounds
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
EP2099796B1 (en) * 2006-11-30 2011-06-01 Genentech, Inc. Aza-indolyl compounds and methods of use
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
CN111615388B (zh) * 2017-07-27 2023-11-14 斯汀格瑞治疗股份有限公司 癌症免疫治疗剂
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
JP7598875B2 (ja) * 2019-04-12 2024-12-12 リボサイエンス リミティド ライアビリティ カンパニー エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体
CN115151253B (zh) * 2019-09-23 2025-04-15 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
CA3291973A1 (en) * 2021-01-29 2026-03-02 Txinno Bioscience Inc. Benzotriazole Derivative Having Inhibitory Activity Against Ectonucleotide Pyrophosphatase-Phosphodiesterase, and Use Thereof

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
US20250101019A1 (en) 2025-03-27
EP4469456A4 (en) 2025-12-31
CN118871439A (zh) 2024-10-29
KR20240142481A (ko) 2024-09-30
CA3247162A1 (en) 2023-08-03
MX2024009216A (es) 2024-08-06
WO2023143520A1 (en) 2023-08-03
AR128383A1 (es) 2024-04-24
EP4469456A1 (en) 2024-12-04
TW202340190A (zh) 2023-10-16
JP2025502943A (ja) 2025-01-30

Similar Documents

Publication Publication Date Title
AU2023213905A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
US11999713B2 (en) Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof
TW202334163A (zh) 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途
WO2024074128A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CN110092787B (zh) 一种化合物或其药用盐或组合物的制备及应用
EP4422623A1 (en) Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
CN112654622B (zh) 并环化合物、其制备方法及用途
WO2023155892A1 (en) Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US20130281438A1 (en) 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS
WO2023174397A1 (en) Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023155871A1 (en) Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2025026377A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
EA052691B1 (ru) Ингибиторы эктонуклеотидпирофосфатазы-фосфодиэстеразы 1 (enpp1) и их применение
HK40116343A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
CN111808080B (zh) 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用
WO2024061300A1 (en) Inhibitors of trex1 and uses thereof
AU2010242394B2 (en) Purine derivative and antitumor agent using same
HK1122797A1 (en) Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
HK1122797B (en) Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same